Solution structure of an analogue of vasoactive intestinal peptide as determined by two-dimensional NMR and circular dichroism spectroscopies and constrained molecular dynamics.
about
The neuropeptide vasoactive intestinal peptide: direct effects on immune cells and involvement in inflammatory and autoimmune diseasesCD4+ T Cell-derived Novel Peptide Thp5 Induces Interleukin-4 Production in CD4+ T Cells to Direct T Helper 2 Cell DifferentiationIdentification of key residues for interaction of vasoactive intestinal peptide with human VPAC1 and VPAC2 receptors and development of a highly selective VPAC1 receptor agonist. Alanine scanning and molecular modeling of the peptideNovel alternatively spliced exon in the extracellular ligand-binding domain of the pituitary adenylate cyclase-activating polypeptide (PACAP) type 1 receptor (PAC1R) selectively increases ligand affinity and alters signal transduction coupling durinVasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions.Structural aspects of gut peptides with therapeutic potential for type 2 diabetes.The effects of vasoactive intestinal peptide in neurodegenerative disorders.Evidence for a direct interaction between the Thr11 residue of vasoactive intestinal polypeptide and Tyr184 located in the first extracellular loop of the VPAC2 receptor.The C-terminal part of VIP is important for receptor binding and activation, as evidenced by chimeric constructs of VIP/secretin.Diffuse pharmacophoric domains of vasoactive intestinal peptide (VIP) and further insights into the interaction of VIP with the N-terminal ectodomain of human VPAC1 receptor by photoaffinity labeling with [Bpa6]-VIP.Peptide agonist docking in the N-terminal ectodomain of a class II G protein-coupled receptor, the VPAC1 receptor. Photoaffinity, NMR, and molecular modeling.Spatial structure model of the CD4 receptor-binding site of the HIV envelope protein gp120.Neuroendocrine cells derived chemokine vasoactive intestinal polypeptide (VIP) in allergic diseases.A complete substitutional analysis of VIP for better tumor imaging properties.
P2860
Q26851670-892EFA15-6235-4924-ACC6-7524B9E90813Q27675896-1F9B611A-3C80-4ABB-A83E-EB25C4F38127Q28143861-2300337A-2E83-4E15-A792-A7C98536DBA9Q33181839-A21A4CEF-DE52-4DA3-BB60-7470B11FDAACQ34238010-08946123-B1D0-4660-B52D-5423977598C7Q38071991-2A0CF1EB-2D17-4E44-BF55-3A55EA5510BDQ38992271-5B072806-BF47-4BD0-8E25-13CCFDC60D67Q40684294-0D2D8BBE-9D54-4421-A531-02C5D83387AAQ41092854-9906501B-1FE0-4990-A298-FF97942D5318Q44973271-81A8B2E7-A8B8-4ED7-8798-5E4AA71BF48AQ46977928-20EA3698-8B8C-492D-99F0-C15D9A2EDE97Q47821421-4B41D328-01B9-41AC-A370-E0C7BB508E83Q47921833-38BACCA4-46A1-4029-A222-8844B092F227Q52955891-FF987B16-57B2-413D-AB5C-1BF9F3FBCE42
P2860
Solution structure of an analogue of vasoactive intestinal peptide as determined by two-dimensional NMR and circular dichroism spectroscopies and constrained molecular dynamics.
description
1989 nî lūn-bûn
@nan
1989 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1989 թվականի մարտին հրատարակված գիտական հոդված
@hy
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
name
Solution structure of an analo ...... onstrained molecular dynamics.
@ast
Solution structure of an analo ...... onstrained molecular dynamics.
@en
type
label
Solution structure of an analo ...... onstrained molecular dynamics.
@ast
Solution structure of an analo ...... onstrained molecular dynamics.
@en
prefLabel
Solution structure of an analo ...... onstrained molecular dynamics.
@ast
Solution structure of an analo ...... onstrained molecular dynamics.
@en
P2093
P356
P1433
P1476
Solution structure of an analo ...... onstrained molecular dynamics.
@en
P2093
P304
P356
10.1021/BI00432A010
P407
P577
1989-03-01T00:00:00Z